Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor necrosis factor-alpha armed GD2 CAR T cells
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Tumor necrosis factor-alpha armed GD2 CAR T cells are an investigational "armored" chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of GD2-positive solid tumors, such as osteosarcoma. These cells are genetically engineered using lentiviral vectors to express a CAR targeting the disialoganglioside GD2 and to locally secrete the cytokine tumor necrosis factor-alpha (TNF-a) upon antigen recognition. This dual approach aims to overcome the challenges of treating solid tumors by combining direct CAR-mediated cytotoxicity with the immunomodulatory effects of TNF-a, which promotes T-cell infiltration and reduces the presence of immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) within the tumor microenvironment. Preclinical data indicate that this localized, antigen-dependent secretion of TNF-a provides superior antitumor efficacy without the systemic toxicity typically associated with systemic cytokine administration.
- Other names
- TNF-alpha armed GD2 CAR T cellsTNF-a armed GD2 CAR T cells
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)GD2TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on tumor necrosis factor-alpha armed GD2 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor necrosis factor-alpha armed GD2 CAR T cells.